Welcome to CSL’s Open Innovation Submission Portal
CSL is a leading global biotech company that develops and delivers innovative biotherapies that help people with life-threatening medical conditions live full lives. Innovation has been in CSL’s DNA for more than a century. CSL has the full spectrum of strengths from research and clinical development to manufacturing and commercialization across six therapeutic areas of expertise. Their strengths enable them to accurately identify, successfully develop, and dependably deliver innovations for patients.
At CSL they believe that for innovation to be fast tracked, they need to partner with the brightest minds in the sector. They know that partnerships can accelerate innovation and delivery of new life-saving and protective medicines and they collaborate and work with external organizations that have unique technologies, assets and equipment, to address patients’ unmet needs around the globe.
If you have an idea related to new products, new technologies or new advancements relating to CSL’s areas of interest, please feel free to share it via the Submission Form. All submissions will be screened by yet2 and if successful, will be shared with CSL. Initial submissions should not include any confidential information.
Core interests for early stage partnering:
- Atherosclerotic plaque stabilization in high-risk patient groups
- Novel targets or biologic therapies to prevent atherosclerotic plaque rupture/erosion and Major Adverse Cardiovascular Events (MACE)
- Homozygous familial hypercholesterolemia
- Gene therapy approaches
- Immune checkpoint inhibitor myocarditis and inflammatory cardiomyopathies
- Novel targets or biologic therapies
- Biomarker approaches for patient stratification
- Autosomal dominant polycystic kidney disease (ADPKD)
- Novel targets or biologic and genetic medicine therapies
- Autoimmune glomerulonephritis indications
- Novel targets or biologic therapies for e.g. membranous nephropathy (pMN) and primary FSGS
- Podocyte health
- Pharmacological intervention to restore podocyte health in rare kidney diseases
- Kidney-targeted drug delivery
- Novel ways to target podocytes, glomerular endothelial cells, mesangial cells, parietal cells, and renal tubular epithelial cells
Click each linked title to submit your solution for each need.
Image by FreePik